1E’s patented platform is able to create safer and more targeted therapies that address chronic and life-threatening indications as well as emerging and evolving pathogens. According to a 2020 article “Send in the senolytics” ,published in Nature Biotechnology 38, 1371-1377, 1E is developing antisense oligonucleotide-based senolytics.